EyePoint Pharmaceuticals, Inc. (EYPT)
EYPT Stock Price Chart
Explore EyePoint Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze EYPT price movements and trends.
EYPT Company Profile
Discover essential business fundamentals and corporate details for EyePoint Pharmaceuticals, Inc. (EYPT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
27 Jan 2005
Employees
165.00
Website
https://eyepointpharma.comCEO
Jay S. Duker
Description
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and development efforts, the company maintains strategic alliances with entities such as Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. Furthermore, a commercial collaboration with ImprimisRx PA, Inc. specifically focuses on the joint promotion of DEXYCU for inflammation following ocular surgery. Incorporated in 1987, the organization was previously known as pSivida Corp. before officially rebranding as EyePoint Pharmaceuticals, Inc. in March 2018. Its corporate headquarters are situated in Watertown, Massachusetts.
EYPT Financial Timeline
Browse a chronological timeline of EyePoint Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is -$0.95, while revenue estimate is $386.57k.
Earnings released on 6 May 2026
EPS came in at -$0.99 falling short of the estimated -$0.79 by -25.32%, while revenue for the quarter reached $696.00k , beating expectations by +97.26%.
Earnings released on 4 Mar 2026
EPS came in at -$0.81 falling short of the estimated -$0.78 by -3.85%, while revenue for the quarter reached $620.00k , missing expectations by -37.65%.
Earnings released on 5 Nov 2025
EPS came in at -$0.85 falling short of the estimated -$0.77 by -10.39%, while revenue for the quarter reached $966.00k , missing expectations by -3.96%.
Earnings released on 6 Aug 2025
EPS came in at -$0.85 falling short of the estimated -$0.67 by -26.87%, while revenue for the quarter reached $5.33m , beating expectations by +29.22%.
Earnings released on 7 May 2025
EPS came in at -$0.65 matching the estimated -$0.65, while revenue for the quarter reached $24.45m , beating expectations by +258.36%.
Earnings released on 5 Mar 2025
EPS came in at -$0.64 falling short of the estimated -$0.54 by -18.52%, while revenue for the quarter reached $11.59m , beating expectations by +41.54%.
Earnings released on 7 Nov 2024
EPS came in at -$0.54 falling short of the estimated -$0.48 by -12.50%, while revenue for the quarter reached $10.52m , missing expectations by -0.34%.
Earnings released on 7 Aug 2024
EPS came in at -$0.58 falling short of the estimated -$0.55 by -5.45%, while revenue for the quarter reached $9.48m , missing expectations by -1.18%.
Earnings released on 8 May 2024
EPS came in at -$0.55 falling short of the estimated -$0.34 by -61.76%, while revenue for the quarter reached $11.68m , beating expectations by +17.07%.
Earnings released on 7 Mar 2024
EPS came in at -$0.33 surpassing the estimated -$0.60 by +45.00%, while revenue for the quarter reached $14.03m , beating expectations by +57.62%.
Earnings released on 1 Nov 2023
EPS came in at -$0.33 surpassing the estimated -$0.62 by +46.77%, while revenue for the quarter reached $15.20m , beating expectations by +74.54%.
Earnings released on 2 Aug 2023
EPS came in at -$0.61 falling short of the estimated $0.41 by -248.78%, while revenue for the quarter reached $9.11m , missing expectations by -82.46%.
Earnings released on 3 May 2023
EPS came in at -$0.56 surpassing the estimated -$0.65 by +13.85%, while revenue for the quarter reached $7.68m , beating expectations by +3.41%.
Earnings released on 2 Mar 2023
EPS came in at -$0.61 surpassing the estimated -$0.63 by +3.17%, while revenue for the quarter reached $10.53m , beating expectations by +1.25%.
Earnings released on 2 Nov 2022
EPS came in at -$0.49 surpassing the estimated -$0.70 by +30.00%, while revenue for the quarter reached $10.01m , missing expectations by -8.37%.
Earnings released on 3 Aug 2022
EPS came in at -$0.52 surpassing the estimated -$0.57 by +8.77%, while revenue for the quarter reached $11.57m , beating expectations by +6.45%.
Earnings released on 4 May 2022
EPS came in at -$0.52 falling short of the estimated -$0.50 by -4.00%, while revenue for the quarter reached $9.29m , missing expectations by -6.00%.
Earnings released on 3 Mar 2022
EPS came in at -$0.59 falling short of the estimated -$0.50 by -18.00%, while revenue for the quarter reached $11.54m , beating expectations by +17.90%.
Earnings released on 3 Nov 2021
EPS came in at -$0.58 falling short of the estimated -$0.47 by -23.40%, while revenue for the quarter reached $9.06m , missing expectations by -7.94%.
Earnings released on 4 Aug 2021
EPS came in at -$0.35 surpassing the estimated -$0.45 by +22.22%, while revenue for the quarter reached $9.01m , meeting expectations.
EYPT Stock Performance
Access detailed EYPT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
